Supreme Court rules 'pay-for-delay' drug deals can be illegal
A divided U.S. Supreme Court ruled Monday that some "pay-for-delay" settlements between drug companies and their competitors violate antitrust laws. The 5-3 decision, a limited victory for the Obama administration, paves the way for federal regulators to challenge such deals in court. Pay-for-delay settlements typically occur when a company develops and patents a new drug to be released into the marketplace. Competitors that wish to introduce a generic version often challenge the patent. Rather than fight the challenge, patent-holding drugmakers have found it more lucrative to simply pay the competitor to keep generics off the market. The two firms then share monopoly profits that are, in some cases, much higher than open competition would yield, critics charge.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Healthcare Costs Start With What We Eat
- IOM Identifies GME Problems, Calls for Finance Changes
- Hospitals Likely to Outsource ICD-10 at Launch
- Revenue Cycles Get a Boost from Simple JPEG Files
- Anatomy of 3 Health System Rebranding Efforts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL